Mölnlycke and AROA partner to expand access to Endoform in the US
Mölnlycke Health Care has entered an exclusive agreement with AROATM to co-promote EndoformTM in the United States in post-acute settings, effective 16 October 2026.
Endoform™ is AROA Biosurgery's regenerative wound care product, used to support healing in chronic and complex wounds. The arrangement combines Endoform, which incorporates AROA’s proprietary AROA ECM™ technology, with Mölnlycke’s established market leading position and commercial reach. It is intended to expand access to Endoform in the US post-acute setting.
The partnership marks an important milestone for Mölnlycke’s post-acute care business in the US, strengthening its advanced wound care offering and supporting its ambition to make effective solutions available to more healthcare professionals and patients.
Brian Ward, AROA Founder and CEO, said “We welcome the opportunity to partner with Mölnlycke, a well-established advanced wound care business known for excellence. Mölnlycke’s deep expertise in wound care and broad commercial footprint provide a strong platform to bring Endoform to more clinicians and patients.”
Craig Kennedy, Mölnlycke VP Americas, commented “Improving wound care requires strong partnerships and continued innovation. Our collaboration with AROA reflects a shared commitment to advancing clinical practice, supporting healthcare professionals, and improving patient outcomes. By adding Endoform to our advanced wound dressing portfolio, we’re expanding the solutions available to clinicians and addressing the diverse needs of the patients they serve.”
AROA will retain ownership of Endoform and AROA ECM and will continue to manufacture, distribute and supply Endoform.
*AROA ECM is a naturally derived extracellular matrix (ECM) technology that supports the body's healing processes by providing the structure and biological signals needed for new tissue growth and repair.
Latest news
-
Martin Ma joins Mölnlycke Zhende as General Manager
In this role, Martin will lead the joint venture's operations and growth strategy in China, with responsibility for commercial execution, organisational leadership, governance and delivery of growth ambitions in one of the world's largest wound care markets.
-
Mölnlycke launches MyFit™ by Biogel® to bring more inclusive sizing to surgical gloves
-
Mölnlycke joins ALPS as Gold strategic partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.